ArticleActa neuropathologica communications2025
Refining prognostic stratification of atypical meningiomas: significance of chromosome 1p deletion and brain invasion.
Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prognostic significance of ACADL and MCM2 in meningiomas: Current evidence and clinical implications.Histology and histopathology · 2026Review
- An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups.Endocrine pathology · 2026Article
- Prognostic stratification of chordoid meningiomas: the role of chromosome 1p/22q Loss.Acta neuropathologica communications · 2026Article
- Novel insights into meningioma brain invasion with spatial transcriptomic profiling.Acta neuropathologica communications · 2026Article
- Concordance of fluorescence in situ hybridization, whole-exome sequencing, and chromosomal microarray for evaluating high-risk molecular features in meningiomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Atypical meningiomas display heterogeneous clinical outcomes, necessitating prognostic markers to identify cases that would benefit of adjuvant treatment. This study investigated the prognostic value of chromosome 1p deletion, assessed by fluorescent in situ hybridization (FISH), in a cohort of 98 primary atypical meningiomas. The accuracy of FISH was validated by comparison with next-generation sequencing (NGS) results. Chromosome 1p deletion was significantly associated with parafalcine/tentorial location, high mitotic index, recurrence, and shorter recurrence-free survival (RFS). Multivariate analysis confirmed the presence of 1p deletion as an independent prognostic factor for shorter RFS. The study also evaluated the immunohistochemical expression of MCM2 and ACADL, which were more frequent in 1p-deleted tumors, but could not reliably predict 1p status. Brain-invasive otherwise benign (BIOB) meningiomas had significantly lower rates of 1p deletion, MCM2 expression, and recurrence, than mitotically active atypical meningiomas. However, recurring BIOB meningiomas showed higher frequencies of MCM2 expression, spontaneous necrosis, and 1p deletion, suggesting that these features may identify BIOB cases with a higher recurrence risk. In conclusion, FISH-detected 1p deletion is a reliable prognostic marker for atypical meningiomas, and its assessment, along with histopathological and immunohistochemical features, can refine the prognostic stratification of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.